The Latest Cardiac and Vascular News
Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy. In October 2019, the first U.S. patients were […]
Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque […]
Conference Call Scheduled for Today, November 4, 2020, at 3:30 PM CT (4:30 PM ET) Revenues of $60.5 million increased 42% sequentially and decreased 6.1% compared to last year Net loss was $2.1 million, or $0.05 per basic and diluted share Management provides fiscal 2021 second quarter revenue guidance of […]
Version II Aim to Release Q1/2021 SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), announced that its joint Venture GBT Tokenize Corp (“GBT/Tokenize”) is currently developing an additional feature for its qTerm device. The additional feature will be a blood […]
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2020 on November 13, 2020 Enrollment Completed in […]
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA® (icosapent ethyl) Approval and Commercialization in Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the […]
TORRANCE, Calif., Nov. 5, 2020 /PRNewswire/ — HeartValveSurgery.com, a leading patient advocacy group for patients with heart valve disease, today released results of a new survey finding that most heart valve patients are “not very aware” of clinical trials, but most patients would consider enrolling in a clinical trial. The nationwide survey was […]
2020 Q3 HIGHLIGHTS compared to Q2 2020: – Revenues were $10,727,000, an increase of $4,354,000, or 68%, compared to $6,373,000 – Pre-tax net income of $5,595,000, an increase of $4,605,000, or 465%, compared to $990,000 – Net income was $4,866,000, or $0.74 per basic share and $0.61 per diluted share, […]
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for […]
